Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
The combination of encorafenib, cetuximab, and mFOLFOX6 has gained accelerated approval from the FDA for the treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation. During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns ...
Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
February 2024: FDA Approvals, Fast Tracks, and Regulatory Action
Mar 1, 2024 · The FDA had a busy February 2024, reviewing and approving a wide range of new therapies and making significant regulatory decisions. Patients with multiple myeloma patients saw the approval of teclistamab-cqyv (Tecvayli) with a reduced dosing schedule, linvoseltamab (REGN5458), and epcoritamab-bysp (Epkinly).
Daratumumab Quadruplet Improves Outcomes in Transplant …
Dec 4, 2024 · The phase 3 CEPHEUS trial (NCT03652064) demonstrated that adding subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) to bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved treatment outcomes for patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for or deferred autologous stem cell transplant (ASCT). 1
September 2024 FDA Roundup: Key Decisions Drive Oncology …
Oct 2, 2024 · FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. ICT01, a humanized anti-BTN3A monoclonal antibody, plus azacitidine and venetoclax (Venclexta) earned fast track designation for the treatment of acute myeloid leukemia in patients 75 or older or those who have comorbidities that preclude standard induction chemotherapy on …
Revolutionizing Lung Cancer Treatment: Advancements Offer New …
Dec 5, 2024 · Lung cancer, the second most common cancer, has long been regarded as one of the most challenging diagnoses in medicine. 1 However, what was once defined by grim prognoses with limited options, is now experiencing a revolution in treatment. The landscape is evolving rapidly thanks to groundbreaking advancements in diagnosis, targeted therapies, clinical trials, and early detection technologies.
CEPHEUS Trial Results: Daratumumab-VRd in Transplant-Ineligible …
Dec 3, 2024 · Saad Z. Usmani, MD, MBA, FACP, FASCO, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, discusses the results and potential impact from the phase 3 CEPHEUS trial (NCT03652064) of daratumumab and hyaluronidase-fihj (subcutaneous daratumumab; Darzalex Faspro) with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple ...
ASH 2024 Preview for Community Oncologists: The Show and …
Dec 3, 2024 · Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event. The American Society of Hematology (ASH) Annual Meeting and ...
Key Advances in Oncology: Top Highlights From ESMO 2024
Sep 18, 2024 · This year's 2024 ESMO Congress brought forth a wave of groundbreaking developments poised to shape the future of oncology. As an essential platform for sharing pivotal cancer research and innovative clinical practices, the ESMO Congress continues to foster vital discourse among the medical community.
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.